The University of Texas MD Anderson Cancer Center received a $574,632 Project Grant award from the National Institute of Biomedical Imaging and Bioengineering under the Discovery and Applied Research for Technological Innovations to Improve Human Health (CFDA 93.286) program. The objective of this 4-year grant, awarded on March 1, 2025, is to develop a rapid, inexpensive microfluidics-based approach for dose-on-demand production of ready-to-inject radiopharmaceuticals that can be adapted to a variety of radiopharmaceutical-related chemistries. The proposed platform aims to simplify raw isotope distribution logistics and facilitate end-user manufacturing and purification of radiopharmaceuticals with minimum resources, thereby reducing barriers to radiopharmaceutical discovery, production, and dissemination.